With a lower price point than the Sense, the Fitbit Versa 3 has a great range of features and a solid battery life of up to six days. It also has a comparable range of sensors and can track skin temperature variation and blood oxygen levels while users sleep. With its integrated GPS, fast charging feature, and sleek color display, the Versa 3 is a well-rounded wearable under $250.00 and a favorite among consumers.
Ōura is a relatively new company that largely focuses on athletes and athletic performance. They are one of the only wearable rings on the market and are a smaller player in the research world — with a few studies published to PubMed. However, they have grown their brand rapidly through large, high-credibility partnerships with the NBA and NASCAR. Their wearable, starting at $299, is comparable in pricing to other wearables.
We think Ōura Ring represents a shift forward for the wearables industry and we expect their clinical presence to grow in the coming years, but the lack of raw data…
Featuring Katherine Eban, investigative journalist and best-selling author, and Dr. Sam Volchenboum
This week we welcome Katherine Eban to Trial by Data to discuss the need for global whistleblower protections, as well as why the industry needs to incentivize drug quality across both name brands and generics. During our time together, we also touch on how companies were able to jump the line for FDA review during the pandemic — and how we can stop such behavior in the future.
Katherine Eban is an investigative journalist and Vanity Fair contributor. Her articles on pharmaceutical counterfeiting, gun trafficking, and coercive…
Although Polar is a device maker focused primarily on fitness, many of the company’s devices have been used in both academic research and clinical trial settings. We recommend this device due to its comprehensive package of sensors that rival other major players in the market and the publicly available API and SDK that allows researchers to examine live heart rate data.
Actigraph is a veteran wearable company that exclusively targets the clinical audience, with the GT9X Link serving as a primary example. We recommend this device for use in the clinical space as its long battery life and simple interface make it an ideal candidate for a variety of participants. In addition, Actigraph’s dedication to data transparency will always be appealing to researchers. However, with rapid innovation in the wearable landscape, the GT9X Link is at risk of falling behind.
Apple’s newest smartwatch has earned both commercial and critical acclaim, with a large range of sensors, sleek design, and ease of use. The Apple Watch is a wearable we will continue to recommend, as we anticipate that Apple will continue its foray into the clinical space with future watches. While not the perfect wearable (especially with its high price point), Apple is on a steady path to become a formidable force in the clinical space.
Featuring Esther Dyson, investor and Executive Founder of Way to Wellville, and Dr. Sam Volchenboum
This week we welcome Esther Dyson to Trial by Data to discuss the social determinants of health and how to best fund and support community well-being. We also discuss the potential impacts of the US election — which was still on the horizon when we recorded this — on the healthcare and pharma industries.
Esther is the executive founder of Way to Wellville, a 10-year nonprofit project dedicated to demonstrating the value of investing in health.
Way to Wellville works in five small communities…
The Sense is Fitbit’s most robust (and expensive) wearable yet. It’s a solid device given its battery life, design, and plethora of sensors. It has also received positive reception for its comfort and ease of use, both of which are incredibly important to ensure optimal levels of participant compliance, especially that they wear the device as often as possible. We identified the Sense as one of our top picks for wearables to use in clinical trials, but it is not without its limitations.
Featuring Dr. Sam Volchenboum
This week we present a special episode in which we discuss the findings of the second volume of our Device Census Report. You can find the report in full on the Litmus website, here.
Our Device Census Reports serve as the only comprehensive investigation of the wearables landscape that examines these devices through the lens of clinical research. Knowing the importance of device selection in clinical trials — and yet also seeing the astounding lack of resources to support researchers — we were motivated to develop our first Device Census Report in 2018.
One of the questions our pharmaceutical customers often ask us is: What is the best wearable device for clinical trials?
It’s a fair question. Despite the accelerated adoption of real world data in clinical trials, there is little industry guidance on wearable device selection for interested pharmaceutical companies to leverage. In fact, when we first surveyed the market two years ago, there was no independent player that was publishing on this topic. Realizing this immense gap in the landscape, we were moved to publish the first volume of the Litmus Health Device Census Report.
To this day, the Litmus’ Device…